SCHEMBL4954837

SCHEMBL4954837

CC(C)(C)OC(=O)NC1CCN(c2cccnc2)CC1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.65
CKS1B P61024 1/20 0.55
SKP1 P63208 1/20 0.55
SKP2 Q13309 1/20 0.55
NPY5R Q15761 2/20 0.53
DRD2 P14416 4/20 0.46
KDM4D Q6B0I6 2/20 0.46
KCNA3 P22001 1/20 0.46
DRD3 P35462 1/20 0.45
OPRM1 P35372 1/20 0.45
OPRD1 P41143 1/20 0.45
OPRK1 P41145 1/20 0.45
OGFRL1 Q5TC84 1/20 0.45
SUV39H2 Q9H5I1 1/20 0.44
PDE10A Q9Y233 1/20 0.44
ADORA2A P29274 2/20 0.44
ADORA2B P29275 1/20 0.44
KDM1A O60341 1/20 0.44
MAOB P27338 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28200582 0.94 GPR119 (0.60) GPR119CKS1BSKP1SKP2NPY5R
SCHEMBL4827630 0.94 GPR119 (0.60) GPR119CKS1BSKP1SKP2NPY5R
SCHEMBL28856276 0.94 GPR119 (0.60) GPR119CKS1BSKP1SKP2NPY5R
SCHEMBL21847896 0.88 GPR119 (0.55) GPR119CKS1BSKP1SKP2KDM4D
SCHEMBL22775604 0.87 GPR119 (0.55) GPR119CKS1BSKP1SKP2KDM4D
SCHEMBL22774285 0.87 GPR119 (0.55) GPR119CKS1BSKP1SKP2KDM4D
SCHEMBL29576568 0.87 GPR119 (0.55) GPR119CKS1BSKP1SKP2KDM4D
SCHEMBL29576692 0.87 GPR119 (0.55) GPR119CKS1BSKP1SKP2KDM4D
SCHEMBL7487448 0.86 GPR119 (0.52) GPR119CKS1BSKP1SKP2NPY5R
SCHEMBL1456142 0.85 CKS1B (0.54) GPR119CKS1BSKP1SKP2DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105408332-B Substituted triazolopyridines 拜耳制药股份公司 2017-05-10 CN disclosed
EP-2079727-B1 KINASE INHIBITOR COMPOUNDS XCOVERY INC (US) 2016-02-17 EP disclosed
US-8524709-B2 Kinase inhibitor compounds TYROGENEX, INC. (US) 2013-09-03 US disclosed
US-20120115866-A1 KINASE INHIBITOR COMPOUNDS TYROGENEX, INC. (US) 2012-05-10 US disclosed
US-8039470-B2 Kinase inhibitor compounds TYROGENEX, INC. (US) 2011-10-18 US disclosed
US-20100261665-A1 Kinase inhibitor compounds XCOVERY, INC. (US) 2010-10-14 US disclosed
US-7683057-B2 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1-acetyl-piperidin-4-yl)-amide; inhibition of 5' AMP-activated protein kinase (AMPK) TYROGENEX, INC. (US) 2010-03-23 US disclosed
US-20090076005-A1 Kinase inhibitor compounds XCOVERY, INC. (US) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076005-A1 Kinase inhibitor compounds MAP3K1, MAP3K20, MAP3K2 GPR119 1851/4885CKS1B 109/4885SKP1 553/4885
US-20120115866-A1 KINASE INHIBITOR COMPOUNDS MAP3K1, MAP3K20, MAP3K2 GPR119 1851/4885CKS1B 109/4885SKP1 553/4885
US-20100261665-A1 Kinase inhibitor compounds MAP3K1, MAP3K20, MAP3K2 GPR119 1851/4885CKS1B 109/4885SKP1 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.